Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Foundations Investment Advisors LLC

Foundations Investment Advisors LLC raised its holdings in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 153.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,646 shares of the biopharmaceutical company’s stock after acquiring an additional 22,209 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $2,637,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of BMY. EWG Elevate Inc. acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth about $57,000. Phocas Financial Corp. acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth about $138,000. RB Capital Management LLC raised its holdings in Bristol-Myers Squibb by 3.2% during the 4th quarter. RB Capital Management LLC now owns 7,258 shares of the biopharmaceutical company’s stock worth $522,000 after buying an additional 226 shares during the period. RNC Capital Management LLC raised its holdings in Bristol-Myers Squibb by 1.2% during the 4th quarter. RNC Capital Management LLC now owns 968,547 shares of the biopharmaceutical company’s stock worth $69,687,000 after buying an additional 11,634 shares during the period. Finally, Carret Asset Management LLC raised its holdings in Bristol-Myers Squibb by 1.5% during the 4th quarter. Carret Asset Management LLC now owns 67,943 shares of the biopharmaceutical company’s stock worth $4,888,000 after buying an additional 975 shares during the period. 75.51% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 240,000 shares of the company’s stock in a transaction that occurred on Monday, February 6th. The stock was sold at an average price of $74.65, for a total transaction of $17,916,000.00. Following the completion of the sale, the chief executive officer now owns 236,104 shares of the company’s stock, valued at $17,625,163.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Giovanni Caforio sold 240,000 shares of the stock in a transaction that occurred on Monday, February 6th. The stock was sold at an average price of $74.65, for a total value of $17,916,000.00. Following the completion of the sale, the chief executive officer now directly owns 236,104 shares of the company’s stock, valued at $17,625,163.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Ann Powell sold 11,183 shares of the stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $74.69, for a total value of $835,258.27. Following the completion of the sale, the executive vice president now directly owns 23,043 shares of the company’s stock, valued at $1,721,081.67. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Stock Down 0.8 %

NYSE:BMY traded down $0.57 during mid-day trading on Friday, reaching $66.53. The stock had a trading volume of 21,616,937 shares, compared to its average volume of 8,457,718. The business’s 50 day moving average is $70.96 and its 200 day moving average is $72.88. Bristol-Myers Squibb has a fifty-two week low of $65.28 and a fifty-two week high of $81.43. The stock has a market cap of $139.63 billion, a P/E ratio of 22.55, a PEG ratio of 1.44 and a beta of 0.46. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.25 and a quick ratio of 1.14.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last announced its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.71 by $0.11. The firm had revenue of $11.41 billion during the quarter, compared to analysts’ expectations of $11.20 billion. Bristol-Myers Squibb had a return on equity of 51.60% and a net margin of 13.71%. The company’s revenue was down 4.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.83 earnings per share. As a group, sell-side analysts predict that Bristol-Myers Squibb will post 8.07 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Monday, April 10th will be given a dividend of $0.57 per share. The ex-dividend date is Thursday, April 6th. This represents a $2.28 dividend on an annualized basis and a yield of 3.43%. Bristol-Myers Squibb’s payout ratio is currently 77.29%.

Wall Street Analyst Weigh In

Several analysts have issued reports on BMY shares. Jefferies Financial Group started coverage on Bristol-Myers Squibb in a report on Monday, March 6th. They set a “hold” rating and a $62.00 price objective on the stock. Morgan Stanley upped their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “underweight” rating in a report on Friday, February 3rd. Wells Fargo & Company upped their target price on Bristol-Myers Squibb from $70.00 to $78.00 and gave the company an “equal weight” rating in a report on Tuesday, January 3rd. StockNews.com started coverage on Bristol-Myers Squibb in a report on Thursday. They issued a “strong-buy” rating on the stock. Finally, Atlantic Securities upped their target price on Bristol-Myers Squibb from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, February 3rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $79.69.

Bristol-Myers Squibb Profile

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.